Discover 1,079 paid clinical trials in Oregon. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Oregon provides numerous opportunities for both healthy volunteers and individuals with specific health conditions to get involved in paid medical research. With major research centers in Portland, Eugene, and Salem actively recruiting, participants can access the latest in treatment options and medical innovation.
Filter
1
Filter results
Results: 1,079
FeaturedActive & Responsive
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
for
Metastatic Colorectal Cancer
Location: Port Jefferson Station NY, New Haven CT,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT04929223
Phase1, Recruiting
Featured
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
for
Obesity or Overweight
Location: Boston MA, Needham MA, New Haven CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07351045
Phase3, Recruiting
Featured
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
for
Alzheimers Disease
Location: Halifax, Boston MA, Watertown MA, New Haven CT,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07170150
Phase3, Recruiting
Featured
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
for
Alzheimers Disease
Location: Halifax, Boston MA, Watertown MA, Newton MA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 50 - 70+
Code: NCT07177352
Phase3, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Hartford CT, Quebec, Westbury NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06793215
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
for
Breast Cancer
Location: East Patchogue NY, The Bronx NY, New Brunswick NJ,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT07100106
Phase1, Phase2, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
for
Breast Cancer
Location: Moncton, The Bronx NY, New York NY, East Brunswick NJ,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06790693
Phase3, Recruiting
Featured
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
for
B-Cell Non-Hodgkins Lymphoma
Location: Boston MA, Albany NY, Virginia Beach VA,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06806033
Phase2, Recruiting
Featured
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,
Location: Scarborough ME, Boston MA, Providence RI, Jamaica NY,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06065748
Phase3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
for
Breast Neoplasms
Location: Rimouski, Boston MA, New Haven CT, Quebec,